ALKEM

** Shares of Alkem Labs ALKE.NS down 6.4% to 5,151 rupees

** Stock top percentage loser on the Nifty Pharma index .NIPHARM, which is down 1.8%

** The pharma co posted a 5.2% YoY increase in quarterly net profit and a 1.5% rise in revenue on Friday, but both fell short of analysts' estimates

** Brokerage J.P. Morgan cuts its FY25/26/27 earnings estimates by 4%/3%/8% due to softer revenue trends

** Co maintained FY25 EBITDA margin target at 19%, indicating a weak Q4 ahead - J.P. Morgan

** Brokerage adds, concerns remain due to weak India growth and lackluster U.S. portfolio

** Stock rose 8.3% in 2024 vs a 39% gain in .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM MEDTECH TO ACQUIRE 100% STAKE IN BOMBAY ORTHO INDUSTRIES

Source text: ID:nBSEhXggz

Further company coverage: ALKE.NS

(([email protected];;))

Feb 4 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - LAUNCHES KOJIGLO SERUM IN INDIA TO MANAGE FACIAL HYPERPIGMENTATION

Source text: ID:nBSE6t76MZ

Further company coverage: ALKE.NS

(([email protected];;))

Jan 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - GETS GST ORDER OF 52.2 MILLION RUPEES, PENALTY OF 52.2 MILLION RUPEES

Source text: [ID:]

Further company coverage: ALKE.NS

(([email protected];))

Dec 25 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• IT AUTHORITY DISALLOWS TAX DEDUCTION

• DISPUTED AMOUNT IS 3.75 BILLION RUPEES

• NO MATERIAL IMPACT ON COMPANY AS NO AMOUNT IS PAYABLE

Source text: ID:nBSE8Pxk02

Further company coverage: ALKE.NS

(([email protected];))

** Shares of Alkem Labs ALKE.NS rise 2.4% to 5,526 rupees

** Stock among top gainers on the Nifty Pharma index .NIPHARM, which is up 1.44%

** The pharma co said on Tuesday it entered into an agreement for equity investment in Sunsure Solarpark by investing 19.5 mln rupees ($229,633)

** Sunsure Solarpark engaged in business of generation, production and distribution of electricity from renewable energy sources

** Eighteen analysts covering the stock on avg have a "hold" rating; median PT is 6,053 rupees - LSEG data

** Stock up 6% YTD vs a 33% gain in .NIPHARM

($1 = 84.9180 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))

Dec 17 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - ENTERED AGREEMENT FOR EQUITY INVESTMENT IN SUNSURE SOLARPARK

• ALKEM LABS - INVESTMENT OF 19.5 MILLION RUPEES

Source text: [ID:]

Further company coverage: ALKE.NS

(([email protected];))

Dec 10 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• APPROVES TRANSFER OF TRADE GENERICS BUSINESS TO ALKEM WELLNESS

• CONSIDERATION EXPECTED TO BE UP TO 7.50 BILLION RUPEES

Source text: ID:nBSE1ZqG4j

Further company coverage: ALKE.NS

(([email protected];))

Nov 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• SEPT-QUARTER CONSOL NET PROFIT 6.89 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 34.15 BILLION RUPEES

Source text: ID:nBSE1s1WRP

Further company coverage: ALKE.NS

(([email protected];))

By Bharath Rajeswaran

Nov 7 (Reuters) - MSCI added five Indian companies to its Global Standard Index late on Wednesday, a move that brokerage Nuvama said would lift the country's weightage on the index to 20%, further narrowing the gap with China.

MSCI said there would be 156 Indian stocks in the index, but that is only one-fourth of China's 598, signalling scope for further inclusion of Indian stocks on the index.

The changes will take place after the markets close on Nov. 25, MSCI said.

The inclusion of the stocks will lift India's weightage in the index to a record 19.8% from 19.3% earlier, narrowing the gap with China, which has slipped to 26.8% from 27%, Nuvama Alternative and Quantitative Research estimated.

It will also likely attract $2.5 billion in passive inflows into India's equity markets, Nuvama said.

China has the highest weightage in the MSCI Global Standard index, while India has been in second place since the end of 2021.

Air conditioner maker Voltas VOLT.NS, realty developer Oberoi Realty OEBO.NS, stock exchange operator BSE BSEL.NS, Kalyan Jewellers KALN.NS, and drug maker Alkem Laboratories ALKE.NS are the latest additions to the index.

Indian markets saw inflows of about $3 billion into equities after the previous MSCI rebalancing in August when seven stocks were added.

"We remain extremely bullish on India, especially with active participation from mutual funds and high net worth individuals (HNIs)/retail investors, and anticipate many more inclusions in the emerging markets index," said Abhilash Pagaria, head of Nuvama research.

Seven existing stocks, including top private lender HDFC Bank HDBK.NS and Tata Power TTPW.NS, saw an increase in their weightage.

HDFC Bank is now the highest-weighted Indian stock in the MSCI indices at 7.08%, surpassing Reliance Industries' RELI.NS 6.08%.

No Indian companies have been removed from the MSCI Global Standard Index so far in November.

Additionally, around 13 firms, including Eureka Forbes EURK.NS, Indegene INEG.NS, and PC Jeweller PCJE.NS, were added to the MSCI Small Cap Index, bringing the total number of small-cap stocks to 525.

(Reporting by Bharath Rajeswaran in Bengaluru; Editing by Abinaya Vijayaraghavan)

(([email protected]; +91 9769003463;))

Oct 10 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• SIGNED A LICENSING AGREEMENT WITH SONNET BIOTHERAPEUTICS HOLDINGS

• SIGNS LICENSING AGREEMENT WITH SONNET BIOTHERAPEUTICS HOLDINGS, INC

• TO DEVELOP, COMMERCIALIZE 'SON-080' FOR TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY

• ALKEM HAS EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE DRUG IN INDIA

• CO TO CARRY OUT CLINICAL DEVELOPMENT OF "SON-080" IN INDIA TO ENABLE REGULATORY FILINGS

Source text for Eikon: ID:nBSE9MwnfJ

Further company coverage: ALKE.NS

(([email protected];))

Sept 27 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS - DENIES CLAIMS OF PAN-D, CLAVAM 625 BATCHES BEING NOT-OF-STANDARD QUALITY

• ALKEM LABS - ALL PRODUCTS MANUFACTURED AT OUR SITES FOLLOW CURRENT GOOD MANUFACTURING PRACTICES

• ALKEM LABS - SAMPLES OF PRODUCTS MENTIONED IN CDSCO LIST ARE SPURIOUS, NOT MANUFACTURED BY ALKEM

Source text for Eikon: ID:nBSE7nqD6X

Further company coverage: ALKE.NS

(([email protected];;))

By Rishika Sadam

BENGALURU, Sept 26 (Reuters) - India's drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents.

The regulator, Central Drugs Standard Control Organisation, releases a monthly list of substandard or fake medicines sold in the country after routine tests across the country by multiple agencies.

The regulator found some drugs as "not of standard quality", including a batch each of Alkem Laboratories' ALKE.NS popular antacid Pan-D, Hetero's anti-infective Cepodem and Shelcal, a vitamin and calcium tablet brand made by privately-owned Pure & Cure Healthcare, and several antibiotics, according to the lists for August.

Sun Pharmaceutical Industries SUN.NS separately informed the regulator of a fake batch of Pantocid, a popular Indian brand of an antacid called pantoprazole. The agency said it is investigating the matter.

Fake, or "spurious", batches of Sun's drug Pulmosil, used to treat high blood pressure in the lungs, and Glenmark Pharmaceuticals' GLEN.NS anti-hypertension drug Telma H, among others, were also notified by the companies to the regulator and were being investigated.

"When a medicine is found to be below quality standards, the drug regulator sends a notice to the manufacturer to check and recall that batch of product. Companies too conduct their own tests on leftover samples to check for the possibility of counterfeit," said Rajiv Singhal, general secretary of drug retailer body All India Organisation of Chemists and Druggists.

The companies did not immediately respond to Reuters' request for comment.

Gastrointestinal, anti-diabetic, vitamins and nutraceutical drug sales were one of the top contributors to the domestic pharma market growth in August, according to research firm Pharmarack.

India, one of the world's largest drug producers and exporters, is working to restore confidence after Indian-made cough syrups were linked to the deaths of children in Gambia, Uzbekistan, and Cameroon.

(Reporting by Rishika Sadam; Editing by Leroy Leo)

(([email protected]))

Aug 9 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABS JUNE-QUARTER CONSOL NET PROFIT 5.45 BILLION RUPEES

• ALKEM LABS JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 30.32 BILLION RUPEES

Source text for Eikon: ID:nBSE34w3Gb

Further company coverage: ALKE.NS

(([email protected];))

** Shares of Alkem Laboratories ALKE.NS rise 3.2% to 5,165 rupees; set to snap four-session losing streak

** Drugmaker says US FDA closed inspection at its manufacturing facility in Baddi and classified it as voluntary action indicated (VAI)

** VAI means objectionable conditions or practices were found, but the agency won't recommend any administrative or regulatory action, as per the regulator's website

** ALKE top pct gainer on Nifty pharma index .NIPHARM which is trading flat

** Mean rating of 18 analysts is "hold"; median PT is 4,780 rupees - LSEG data

** Stock down 0.2% this year, erasing most YTD losses, but underperforms NIfty pharma index's 16% climb

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

June 6 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - CO AGREED TO INVEST 300 MILLION RUPEES IN SHARES OF HAYSTACKANALYTICS

• ALKEM LABORATORIES - PROPOSED INVESTMENT WILL HELP CO TO PARTICIPATE IN GROWING DIAGNOSTIC SPACE

Source text for Eikon: ID:nBSEsvr73

Further company coverage: ALKE.NS

(([email protected];))

May 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES - CO GOT TAX ORDER FOR DEMAND OF 12.9 MILLION RUPEES

Source text for Eikon: ID:nBSEbSQzjg

Further company coverage: ALKE.NS

(([email protected];))

** Shares of India's Alkem Laboratories ALKE.NS down 2.5% at 4,880 rupees after falling as much as 3.7% earlier

** Drugmaker said it received ten post-inspection observations from U.S. Food and Drug Administration (US FDA)

** Stock set to snap four straight quarterly gains, down 6.7% so far

** Avg rating of 21 analysts is "hold", while shares currently trading ~3% higher than median TP of 4,748 rupees - LSEG data

** YTD stock has fallen 6.6% after a 74.5% surge in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

March 27 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD - US FDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY LOCATED AT BADDI, INDIA

• ALKEM LABORATORIES LTD - RECEIVED FORM 483 WITH TEN (10) OBSERVATIONS

Source text for Eikon: ID:nBSEc45FK2

Further company coverage: ALKE.NS

(([email protected];;))

March 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• GOT GST ORDER WITH PENALTY OF 1.8 MILLION RUPEES

Further company coverage: ALKE.NS

(([email protected];))

** Shares of Alkem Laboratories ALKE.NS rise as much as 2.2% to 5099 rupees; last up 2%

** Drugmaker says U.S. FDA issued Establishment Inspection Report for co's API manufacturing facility at Mandva and inspection has been classified as Voluntary Action Indicated (VAI)

** Stock set to snap fourth straight sessions of losses

** Stock has been above its 100-day SMA since late Oct, and above its 200-day SMA since March, indicating bullish sentiment

** Avg rating of the 22 analysts is "hold" and median PT is 4,716 rupees, ~7% lower than current price - LSEG data

** Stock rose 74.5% in 2023, gaining most in a year since its listing in 2015

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected] ;))

Feb 28 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• CLOSURE OF US FDA INSPECTION AT COMPANY'S API MANUFACTURING FACILITY LOCATED AT MANDVA

• US FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT (EIR)

• INSPECTION HAS BEEN CLASSIFIED AS VOLUNTARY ACTION INDICATED AND WAS CLOSED ACCORDINGLY

  
  

Further company coverage: ALKE.NS

(([email protected];))

Adds company's response, updates shares

** Shares of Alkem Laboratories ALKE.NS down 7% at 5,039.90 rupees

** ALKE fell more than 14% earlier, its biggest intraday decline since March 2020

** India's income tax department found "bogus" tax claims worth over 10 bln rupees ($121 million), India Today reports, citing sources

** ALKE denied allegations in an exchange filing

** "Fully cooperated with the Income Tax Department officials during their survey proceedings in September 2023" - ALKE

** IT department did not immediately respond to Reuters' request for comment

** Nearly 2.1 mln shares change hands, its busiest session since August 2020

** Avg rating of 22 analysts on ALKE is "hold"; median PT is 4,716 rupees - LSEG data

** Stock down 3% YTD after rising 74.5% in 2023

($1 = 82.8720 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Jan 12 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• NAMES NITIN AGRAWAL AS THE CHIEF FINANCIAL OFFICER

Source text for Eikon: [ID:]

Further company coverage: ALKE.NS

(([email protected];))

Dec 1 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• US FDA INSPECTION AT COMPANY'S API MANUFACTURING FACILITY LOCATED AT MANDVA

• CO RECEIVED FORM 483 WITH THREE OBSERVATIONS

• NO DATA INTEGRITY OBSERVATION

• US FDA HAD CONDUCTED INSPECTION FROM 27 NOVEMBER TO 1 DECEMBER

Source text for Eikon: ID:nBSE5T2THF

Further company coverage: ALKE.NS

(([email protected];;))

** Shares of Alkem Laboratories ALKE.NS up as much as 6.8% to all-time high of 4,300 rupees; biggest intraday pct jump since May 13, 2022

** Drugmaker's stock closed 5.3% up on Tuesday after it posted Q2 profit jump; on track to rise for ninth straight session, if gains hold

** Nomura upgrades rating to "buy"; says easing pricing pressure in U.S. to drive sales, cooling raw material costs to improve margins

** Antique Stock Broking raises PT to 3,962 rupees from 3,496 rupees; says ALKE's margins to improve towards 19% by FY26 on growth in India and U.S. business

** Avg rating of 23 analysts tracking the stock at "hold"; median PT is 3,700 rupees - LSEG data

** Stock last up 5.7%, extending YTD gains to ~43%

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Nov 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• INDIA'S ALKEM LABORATORIES LTD SEPT-QUARTER CONSOL NET PROFIT 6.21 BILLION RUPEES VERSUS PROFIT 3.31 BILLION RUPEES

• ALKEM LABORATORIES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 34.4 BILLION RUPEES VERSUS 30.79 BILLION RUPEES

Source text for Eikon: ID:nBSE843kC2

Further company coverage: ALKE.NS

(([email protected];))

** Shares of Alkem Laboratories ALKE.NS rise as much as 2.7% to 3,656.9 rupees

** Analysts at J.P. Morgan initiate coverage with "overweight" rating, price target of 3,985 rupees

** Expects long-term growth to be healthy backed by dominant position in acute therapies, market share gain in chronic segment and growth in trade generic business - JPM

** Says ALKE benefits from consistent outperformance in India, volume led growth and leadership in acute therapies

** Five of the 23 analysts covering the stock have "buy" or "strong buy" rating, 9 have "hold" while 9 rate it at "sell" or "strong sell"; median PT is 3,600 rupees - LSEG data

** Stock up 21% YTD

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of Alkem Laboratories ALKE.NS fall as much as 3.39% to 3-month low of 3,452.40 rupees

** Drug maker among top losers in pharma index .NIPHARM, which is down 1.75%

** Slide after HSBC cuts target price to 3,910 rupees from 3,945 rupees and reiterates "hold"

** HSBC expects ALKE to report subdued results in September quarter due to slowdown in acute therapies, low volumes in anti-infectives segments

** Lowers India sales growth estimates to 7.9% for fiscal 2024 from earlier estimate of 9%

** Of the 22 analysts tracking ALKE, one has "strong buy", three have "buy", nine "hold", five "sell" and four "strong sell"; median TP is 3,600 rupees - LSEG data

** ALKE up 16.3% YTD, including session's slide, compared with 19.5% rise in index .NIPHARM

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

Sept 25 (Reuters) - Alkem Laboratories Ltd ALKE.NS:

• ALKEM LABORATORIES LTD- COMPANY AND BIOSERGEN AB HAVE ENTERED INTO A CO-DEVELOPMENT AND LICENSE AGREEMENT

• ALKEM LABORATORIES LTD - WILL INVEST IN CLINICAL DEVELOPMENT OF BSG005 AND WILL BE GRANTED AN EXCLUSIVE LICENSE TO MARKET IT IN INDIA

• ALKEM LABORATORIES LTD - AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF BIOSERGEN'S NOVEL POLYENE MACROLIDE ANTIFUNGAL PRODUCT BSG005

• ALKEM WILL MANAGE FIRST CLINICAL PATIENT TRIAL

Source text for Eikon: ID:nBSE7yb9PV

Further company coverage: ALKE.NS

(([email protected];))